NTRK
Showing 76 - 93 of 93
PLAsma Genomic Testing in Advanced Non-Small Cell Lung Cancer:
Not yet recruiting
- Non-small Cell Lung Cancer
- ctDNA liquid biopsy - Roche Avenio Assay
- (no location specified)
Sep 14, 2022
NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- MK-2870
- +2 more
- (no location specified)
Oct 3, 2023
CNS Tumor, Infantile Fibrosarcoma, Recurrent Acute Leukemia Trial in Canada, United States (Larotrectinib Sulfate)
Active, not recruiting
- Central Nervous System Neoplasm
- +4 more
- Larotrectinib Sulfate
-
Birmingham, Alabama
- +81 more
Jan 24, 2023
Cancer, Advanced Solid Tumor Trial in Kettering (lorlatinib, encorafenib + binimetinib, talazoparib)
Recruiting
- Cancer
- Advanced Solid Tumor
- lorlatinib
- +4 more
-
Kettering, OhioKettering Health Network
Oct 14, 2022
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Terminated
- Solid Tumor
- +2 more
- PLX7486 TsOH
-
Los Angeles, California
- +3 more
Aug 1, 2018
Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc
Unknown status
- Lung Cancer
- Molecular analysis of surnatant
-
Toulouse, FranceNicolas Guibert
Nov 9, 2020
Genetic Predictors of Lithium Response in Bipolar Disorder
Completed
- Bipolar Disorder
- Lithium treatment
-
San Diego, CaliforniaVA San Diego Healthcare System, San Diego, CA
Jan 17, 2020
Chinese Non-Small Cell Lung Cancer Rare Driver Gene Mutation
Recruiting
- Chinese
- Non-Small Cell Lung Cancer
- nonIntervention
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Dec 24, 2019
Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine, Cetuximab)
Not yet recruiting
- Colorectal Cancer
- Cetuximab, Capecitabine
- Cetuximab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Feb 7, 2020
Obesity Trial in Paris La Defense
Recruiting
- Obesity
-
Paris La Defense, FrancePitié-Salpêtrière Hospital, AP-HP -Nutrition department
Oct 21, 2020
Non Small Cell Lung Cancer Trial in Italy (Cabozantinib 20 MG, Cabozantinib 40 MG, Cabozantinib 60 MG)
Recruiting
- Non Small Cell Lung Cancer
- Cabozantinib 20 MG
- +2 more
-
Bologna, Italy
- +10 more
Oct 17, 2019
Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma Trial
Completed
- Recurrent Thyroid Gland Carcinoma
- +4 more
- Laboratory Biomarker Analysis
- Selumetinib
-
Tampa, Florida
- +5 more
Dec 2, 2016
Transient Receptor Potential Vanilloid One Receptor Expression
Completed
- Epigastric Pain
- +3 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Oct 21, 2015